Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for idiopathic pulmonary fibrosis and application thereof

A pulmonary fibrosis, idiopathic technology, applied in the field of medicine, to achieve the effect of improving the quality of life, slowing down acute exacerbations, and alleviating pulmonary interstitial fibrosis

Active Publication Date: 2021-05-21
GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there is no report on dextromethorphan against idiopathic pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for idiopathic pulmonary fibrosis and application thereof
  • Pharmaceutical composition for idiopathic pulmonary fibrosis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1: The patient, male, 54 years old, the main clinical symptoms of the patient were intermittent cough, expectoration, and chest tightness for 3 years, which aggravated for 1 month. The patient was diagnosed with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and was given oral pirfenidone capsules starting from 200 mg each time, 3 times a day, and the dose was increased by 200 mg each week, and then gradually increased by 600 mg each time. 3 times a day, plus dextromethorphan 7.5mg once a day. After 1 month of drug treatment, the patient had no further progression of idiopathic pulmonary fibrosis on chest CT scan. After continuing to take the medicine orally for 3 months, the patient felt that the symptoms such as cough and chest tightness were relieved compared with before, and the chest CT showed that the ground-glass opacities and grid shadows in both lungs were relieved compared with before. The re-examination of the patient's lung function...

Embodiment 2

[0017] Example 2: The patient, male, 82 years old, the main clinical symptoms of the patient were intermittent cough and expectoration for more than 10 years, which aggravated with wheezing for 1 week. The patient was diagnosed with idiopathic pulmonary fibrosis (IPF) on CT scan 10 years ago. The patient did not receive any special treatment. In the past 1 week, the patient felt that his cough had worsened with wheezing. The examination of both lungs showed diffuse interstitial changes, and the interstitial fibrosis in both lungs was worse than before. , consider the patient as AE-IPF. Oral administration of pirfenidone capsules starting from 200mg each time, 3 times a day, increasing the dose by 200mg each time a week, and then gradually increasing 400mg 3 times a day for anti-fibrosis treatment, and at the same time adding dextromethorphan 7.5mg a day 1 time. A one-month re-examination of chest CT showed no significant progression of interstitial fibrosis in both lungs. Th...

Embodiment 3

[0018] Embodiment 3: The patient, male, 70 years old, the main clinical symptom of the patient is intermittent wheezing for 2 years, which aggravates with wheezing for 1 week. The patient's chest CT scan in May 2019 showed increased diffuse ground-glass shadows, mesh shadows, and honeycomb shadows in both lungs, and pulmonary interstitial fibrosis had progressed compared with before. Lung function check showed FEV1% pred 57.8%, FVC% pred 44.6%. The patient took oral pirfenidone capsules starting from 200mg each time, 3 times a day, and increased the dose by 200mg each time a week, and then gradually increased 400mg 3 times a day for anti-fibrosis treatment. At the same time, dextromethorphan 7.5mg was added every day 1 time a day. After 4 months of oral administration, the patient's re-examination of chest CT showed that the interstitial fibrosis of both lungs was less than before, and the ground-glass opacity of both lungs was less than before. The results are as follows: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for idiopathic pulmonary fibrosis and application thereof. The pharmaceutical composition for the idiopathic pulmonary fibrosis comprises pirfenidone and dextromethorphan. The content of the pirfenidone is 200 to 600 mg, and the content of the dextromethorphan is 7.5 mg. The pharmaceutical composition for resisting the idiopathic pulmonary fibrosis is an oral medicine. An administration mode of the pharmaceutical composition for resisting the idiopathic pulmonary fibrosis is that the single dose of the pirfenidone is 200-600 mg, and the pirfenidone is taken for three times a day; and the single dose of the dextromethorphan is 7.5 mg, and the dextromethorphan is taken once a day. According to the administration dosage of the pirfenidone, the single dose of the pirfenidone is increased by 200-400 mg per week. The dosage of the pirfenidone is increased to 400-600 mg each time within two weeks. According to the invention, acute exacerbation of pulmonary fibrosis can be slowed down, pulmonary interstitial fibrosis is relieved compared with the previous condition, and the life quality is improved.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a drug combination for idiopathic pulmonary fibrosis and its application. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) is a special type of chronic progressive fibrotic interstitial pneumonia, characterized by destruction of alveolar structure and abnormal deposition of extracellular matrix in alveolar space and lung interstitium. Imaging studies mainly showed symmetrical subpleural distribution of both lungs, grid-like shadows and honeycombing lungs dominated by the base of the lower lungs. The onset of the disease is insidious, and the prognosis is extremely poor. The clinical manifestations are progressive aggravation of dyspnea and dry cough. As the disease progresses in the late stage, clubbing and double lower lung crackles may appear. In the early stage of the disease, alveolitis is the main form, and a large number of inflammatory cells such as monocytes and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/485A61K31/4418A61P11/00
CPCA61K31/4418A61K31/485A61P11/00A61K2300/00Y02A50/30
Inventor 冯靖曹洁刘娜娜魏路清宁文
Owner GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com